Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients

Jew, Scott; Bujarski, Sean; Soof, Camilia; Chen, Haiming; Safaie, Tahmineh; Li, Mingjie; Sanchez, Eric; Wang, Cathy; Emamy-Sadr, Marsiye; Swift, Regina A.; Rahbari, Ashkon; Patil, Saurabh; Souther, Eric; Spektor, Tanya M.; Berenson, James R.

doi:10.1111/bjh.16673

Cited by 12 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to establish the normal range for this study, we evaluated 205 healthy donors with a median age of 62 years (range, 24–87), which was similar to that of our MM patients, and determined a median normal sBCMA level of 37·51 ng/ml (standard deviation, 22·54 ng/ml) 14 . sBCMA levels were found to be independent of age, sex and race within this control population.…”

Section: Methodsmentioning

confidence: 99%

Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Jew

Chang²,

Bujarski

et al. 2020

Br J Haematol

Self Cite

View full text Add to dashboard Cite

Serum B-cell maturation antigen (sBCMA) is a novel biomarker for B-cell malignancies. A normal reference range (<82Á59 ng/ml) has been recently established but the impact of achieving normal levels to outcomes for patients receiving treatment for B-cell malignancies has not been studied. We first found that among multiple myeloma (MM) patients starting a new treatment, those who begin treatment within normal sBCMA limits (<82Á59 ng/ml) have improved progression-free survival (PFS; P = 0Á0398) and overall survival (OS; P = 0Á0217) than those who do not. Furthermore, among patients who begin treatment with elevated (≥82Á59 ng/ml) sBCMA levels, we assessed the relationship of a decrease in sBCMA to the normal range to OS and found that those who normalize sBCMA demonstrated improved OS (P = 0Á0078). Normalizing patients also experienced a markedly improved overall response rate (P < 0Á0001). Moreover, all patients who achieved complete remission (CR) showed normalization of sBCMA, and time to normalization (median 0Á9 months) was faster than time to CR (5Á0 months; P = 0Á0036) for these patients. These results suggest that normalization of sBCMA may be an accurate predictor of OS for MM patients during treatment and predict for a higher likelihood of response.

show abstract

Section: Methodsmentioning

confidence: 99%

Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Jew

Chang²,

Bujarski

et al. 2020

Br J Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The incidence of SLE is significantly higher in females than males. Previous studies in MM indicated that sBCMA levels are independent of gender, age, serum β-2M, hemoglobin, and creatinine, 12,35 enabling its reliable clinical exploitation as a biomarker. However, adult cohorts are unrepresentative of children.…”

Section: Discussionmentioning

confidence: 99%

Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement

Lin

Cheng

et al. 2023

Lupus

View full text Add to dashboard Cite

Objective The aim of this study was to investigate serum levels of soluble B-cell maturation antigen (sBCMA) in childhood-onset systemic lupus erythematous (cSLE) patients with renal involvement, and to elucidate their association with clinical characteristics. Methods 116 cases of cSLE patients with renal involvement (84 females and 32 males; median age 11.6 (10.1, 12.9) years) hospitalized in Department of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-sen University and 31 healthy controls (HCs) were enrolled. Serum concentrations of sBCMA were determined using enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory information of cSLE patients were retrospectively analyzed. Results Serum sBCMA levels were significantly increased in primary cSLE when compared with treated cSLE patients and HCs, whereas there was no significant difference between treated cSLE patients and HCs. Patients with high disease activity displayed higher serum sBCMA levels compared with those with no or mild to moderate disease activity. Positive correlation was observed between serum sBCMA levels and systemic lupus erythematosus disease activity index-2K (SLEDAI-2K), antinuclear antibody titers, anti-double-stranded DNA titers, erythrocyte sedimentation rate, and immunoglobulin G levels, while sBCMA levels were negatively correlated with blood white blood cell count, hemoglobin, platelet count, complement C3 and C4 levels. Serum sBCMA levels decreased as disease ameliorated after treatments among 11 cases with follow-up examinations. Conclusions In cSLE patients with renal involvement, serum sBCMA levels correlated significantly with disease activity, immunological, and hematological parameters, but not with renal parameters. Our results suggest the potential and significance of serum sBCMA as a biomarker in cSLE patients.

show abstract

“…In fact, the first normal reference range was proposed (<82Á59 ng/ml), based on the determination of sBCMA levels in 196 healthy subjects. 50 Better outcomes were observed among patients who began treatment within this reference range compared with those whose levels were elevated. 50,51 Overall, BCMA plays a crucial role in the proliferation and long-term survival of MM cells, inducing their evasion from apoptosis and supporting the production of immunosuppressive molecules.…”

Section: Bcma As An Optimal Target For Immunotherapymentioning

confidence: 97%

“…48 It was confirmed that sBCMA is elevated in MM and correlates with disease status and survival. Patients responding to the treatment had lower sBCMA than those with progressive disease, 49,50 and patients with a higher sBCMA level had significantly shorter progression-free survival (PFS) and OS. That indicates that sBCMA might be a new biomarker for the diagnosis of MM, and can also be a tool for the prognosis and monitoring of treatment response.…”

Section: Bcma As An Optimal Target For Immunotherapymentioning

confidence: 99%

“…Moreover, it provides a potential tool for tracking non‐secretory MM as well. In fact, the first normal reference range was proposed (<82·59 ng/ml), based on the determination of sBCMA levels in 196 healthy subjects 50 . Better outcomes were observed among patients who began treatment within this reference range compared with those whose levels were elevated 50,51 …”

Section: Bcma As An Optimal Target For Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

2020

View full text Add to dashboard Cite

Remarkable advances have been achieved in the treatment of multiple myeloma (MM) in the last decade, which saw targeted immunotherapy, represented by anti-CD38 monoclonal antibodies, successfully incorporated across indications. However, myeloma is still considered curable in only a small subset of patients, and the majority of them eventually relapse. B-cell maturation antigen (BCMA) is expressed exclusively in mature B lymphocytes and plasma cells, and represents an ideal new target for immunotherapy, presented by bispecific antibody (bsAb) constructs, antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) cells. Each of them has proved its efficacy with the potential for deep and long-lasting responses as a single agent therapy in heavily pretreated patients. As a result, belantamab mafodotin was approved by the United States Food and Drug Administration for the treatment of relapsed/refractory MM, as the first anti-BCMA agent. In the present review, we focus on monoclonal antibodies targeting BCMA -bsAbs and ADCs. The data from preclinical studies as well as first-inhuman clinical trials will be reviewed, together with the coverage of their constructs and mechanisms of action. The present results have laid the groundwork for the ongoing or upcoming clinical trials with combinatory regimens, which have always been a cornerstone in the treatment of MM.

show abstract

Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients

Cited by 12 publications

References 13 publications

Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement

Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

Contact Info

Product

Resources

About